[1] Baran DA.New directions in immunosuppression after heart transplantation.Nat Rev Cardiol. 2013;10(7):422-427. [2] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. [3] Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.ExpHematol. 2003;31(10):890-896. [4] Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation.Transplantation. 2003;75(3): 389-397. [5] Jang IK, Yoon HH, Yang MS, et al. B7-H1 inhibits T cell proliferation through MHC class II in human mesenchymal stem cells.Transplant Proc. 2014;46(5):1638-1641. [6] Cornelissen AS, Maijenburg MW, Nolte MA, et al. Organ-specific migration of mesenchymal stromal cells: Who, when, where and why. Immunol Lett. 2015;168(2): 159-169. [7] Hall BM.CD4+CD25+ T Regulatory Cells in Transplantation Tolerance: 25 Years On.Transplantation. 2016;100(12):2533- 2547. [8] Kavanagh H, Mahon BP.Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells.Allergy. 2011;66(4):523-531. [9] Luz-Crawford P, Kurte M, Bravo-Alegría J, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells.Stem Cell Res Ther. 2013;4(3):65. [10] 穆思捷.人羊膜间充质干细胞体外上调类风湿关节炎患者外周血Treg细胞比例[D].遵义:遵义医科大学,2015.[11] Kaundal U, Bagai U, Rakha A. et al. Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation.J Transl Med. 2018; 16(1):31. [12] Zhao X, Ding HF, Guo CS, et al. In vitro effects of mesenchymal stem cells on secreting function of T lymphocytes and CD4?CD25? T cells from patients with immune thrombocytopenia. ZhonghuaXue Ye XueZaZhi. 2013;34(12):1015-1019. [13] Cho KS, Kim YW, Kang MJ, et al. Immunomodulatory Effect of Mesenchymal Stem Cells on T Lymphocyte and Cytokine Expression in Nasal Polyps.Otolaryngol Head Neck Surg. 2014;150(6):1062-1070. [14] Tobin LM, Healy ME, English K, et al. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease.Clin ExpImmunol. 2013;172(2): 333-348. [15] Hsu WT, Lin CH, Chiang BL, et al. Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-γ+ CD4+ regulatory T cells to control transplant arteriosclerosis.J Immunol. 2013;190(5):2372-2380. [16] Cagliani J, Grande D, Molmenti EP, et al. Immunomodulation by Mesenchymal Stromal Cells and Their Clinical Applications. J Stem Cell Regen Biol. 2017;3(2):1-26. [17] Franquesa M, Hoogduijn MJ, Bestard O, et al. Immunomodulatory effect of mesenchymal stem cells on B cells.Front Immunol. 2012;3:212. [18] Rosado MM, Bernardo ME, Scarsella M, et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells.Stem Cells Dev. 2015; 24(1):93-103. [19] Tabera S, Pérez-Simón JA, Díez-Campelo M, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes.Haematologica. 2008;93(9): 1301-1309. [20] Asari S, Itakura S, Ferreri K, et al. Mesenchymal stem cells suppress B-cell terminal differentiation.ExpHematol. 2009; 37(5):604-615. [21] Healy ME, Bergin R, Mahon BP, et al. Mesenchymal stromal cells protect against caspase 3-mediated apoptosis of CD19(+) peripheral B cells through contact-dependent upregulation of VEGF.Stem Cells Dev. 2015; 24(20): 2391-2402. [22] Reinders ME, Hoogduijn MJ.NK Cells and MSCs: Possible Implications for MSC Therapy in Renal Transplantation.J Stem Cell Res Ther. 2014;4(2):1000166. [23] Spaggiari GM, Capobianco A, Becchetti S, et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006;107(4):1484-1490. [24] Spaggiari GM, Capobianco A, Abdelrazik H, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2.Blood. 2008;111(3): 1327-1333. [25] Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells.Stem Cells. 2006;24(1):74-85. [26] Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.Stem Cells. 2008;26(1):212-222. [27] Poggi A, Prevosto C, Massaro AM, et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors.J Immunol. 2005;175(10):6352-6360. [28] Casado JG, Tarazona R, Sanchez-Margallo FM.NK and MSCs crosstalk: the sense of immunomodulation and their sensitivity.Stem Cell Rev. 2013;9(2):184-189. [29] Chatterjee D, Tufa DM, Baehre H, et al. Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells.Blood. 2014;123(4):594-595. [30] Fu B, Tian Z, Wei H.Subsets of human natural killer cells and their regulatory effects.Immunology. 2014;141(4):483-489. [31] Hirata N, Yanagawa Y, Satoh M, et al. Dendritic cell-derived TNF-alpha is responsible for development of IL-10-producing CD4+ T cells.Cell Immunol. 2010;261(1):37-41.[32] van den Berk LC, Jansen BJ, Snowden S, et al. Cord blood mesenchymal stem cells suppress DC-T Cell proliferation via prostaglandin B2.Stem Cells Dev. 2014;23(14): 1582-1593. [33] Li FR, Wang XG, Deng CY, et al. Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells.Clin ExpImmunol. 2010;161(2):357-363. [34] Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.Blood. 2005;105(10):4120-4126. [35] Spaggiari GM, Abdelrazik H, Becchetti F, et al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2.Blood. 2009;113(26): 6576-6583. [36] Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood. 2005; 105(5):2214-2219. [37] Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.Nat Med. 2009; 15(1):42-49. [38] Choi H, Lee RH, Bazhanov N, et al. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF- κB signaling in resident macrophages.Blood. 2011; 118(2): 330-338. [39] François M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012;20(1):187-195. [40] Bouffi C, Bony C, Courties G, et al. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis.PLoS One. 2010;5(12): e14247. [41] Liu XH, Kirschenbaum A, Yao S, et al. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.Ann N Y Acad Sci. 2006; 1068:225-233. [42] Gao S, Mao F, Zhang B, et al. Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-κB and signal transducer and activator of transcription 3 pathways.ExpBiol Med (Maywood). 2014;239(3):366-375. [43] Squillaro T, Peluso G, Galderisi U.Clinical Trials With Mesenchymal Stem Cells: An Update.Cell Transplant. 2016; 25(5):829-848. [44] Vanikar AV, Trivedi HL, Feroze A, et al. Effect of co-transplantation of mesenchymal stem cells and hematopoietic stem cells as compared to hematopoietic stem cell transplantation alone in renal transplantation to achieve donor hypo-responsiveness. Int Urol Nephrol. 2011; 43(1):225-232. [45] Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.JAMA. 2012;307(11):1169-1177. [46] Vanikar AV, Trivedi HL, Kumar A, et al. Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic stem cells helps safe minimization of immunosuppression in renal transplantation - single center experience.Ren Fail. 2014; 36(9):1376-1384. [47] Pan GH, Chen Z, Xu L, et al. Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study. Oncotarget. 2016;7(11):12089-12101. [48] Obermajer N, Popp FC, Johnson CL, et al. Rationale and prospects of mesenchymal stem cell therapy for liver transplantation.CurrOpin Organ Transplant. 2014; 19(1):60-64. [49] Menard C, Pacelli L, Bassi G, et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.Stem Cells Dev. 2013;22(12):1789-1801. [50] Haarer J, Johnson CL, Soeder Y, et al. Caveats of mesenchymal stem cell therapy in solid organ transplantation. Transpl Int. 2015;28(1):1-9. [51] Teo GS, Yang Z, Carman CV, et al. Intravital imaging of mesenchymal stem cell trafficking and association with platelets and neutrophils.Stem Cells. 2015;33(1):265-277. [52] Vandeputte C, Taymans JM, Casteels C, et al. Automated quantitative gait analysis in animal models of movement disorders.BMC Neurosci. 2010;11:92. [53] 徐璐,廖德怀,陈正,等.肾移植中经移植肾动脉输注骨髓间充质干细胞3例报告[J].中国组织工程研究,2010,14(53):10049-10052. |